Ogier advises Zura Bio Limited on its business combination with JATT Acquisition Corp

Ogier has acted as Cayman Islands counsel to biotechnology company Zura Bio Limited on its business combination with JATT Acquisition Corp, a publicly traded special purpose acquisition company (SPAC).

Upon the completion of the business combination, JATT Acquisition Corp changed its name to Zura Bio Limited and the combined entity began trading on Nasdaq as a clinical-stage biotechnology company focused on immunology.

The merger results in approximately US$65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions.

The Ogier team was led by partners Cynthia Anandajayasekeram and Angus Davison, with managing associate Tom McLaughlin and associate Laura O'Byrne.

"Our Corporate team in the Cayman Islands has extensive experience advising on de-SPAC transactions and we are delighted to have assisted Zura Bio on this important milestone for the company," said Cynthia.

A separate Ogier team led by partner Bradley Kruger, with associate Caroline Dekker, also advised one of Zura Bio's major shareholders on the Cayman Islands aspects of a pre-business combination restructuring.